Bezwoda W R, Mansoor N, Dansey R
Department of Medicine, University of the Witwatersrand Medical School, Johannesburg, South Africa.
Oncology. 1987;44(6):345-9. doi: 10.1159/000226509.
Tumour aromatase, oestrogen (E) and progesterone (P) receptor (R) measurements were carried out in biopsies from 29 patients with advanced or recurrent breast cancer. Patients were then treated with aminoglutethimide according to one of two dosage regimens: (a) aminoglutethimide 1000 mg/day + hydrocortisone 20 mg/day, and (b) aminoglutethimide 250 mg/day. Tumour aromatase values varied from 0.05 to 2.07 pmol ER produced/mg protein/h and ER and PR values from less than 1 to 249 and less than 1 to 132 fmol of steroid bound/mg protein, respectively. There was no correlation between aromatase values and either ER or PR and also no correlation between ER and PR and response to aminoglutethimide. Tumour aromatase values did however correlate with response to treatment. Mean aromatase levels for responders (1.18 +/- 0.64 pmol E produced/mg protein/h) were significantly higher than those of non-responders (0.34 +/- 0.27) (t = 5.20, DF 27; p less than 0.005). Ten out of fourteen patients with aromatase values greater than 0.5 pmol ER produced/mg protein/h responded, whereas 0 out of 15 patients with tumour aromatase values less than this responded. Responses were seen at both dosages of aminoglutethimide. It is concluded that tumour aromatisation will be a useful measurement in predicting response to aromatase inhibitors.
对29例晚期或复发性乳腺癌患者的活检组织进行了肿瘤芳香化酶、雌激素（E）和孕激素（P）受体（R）检测。然后根据两种剂量方案之一用氨鲁米特治疗患者：（a）氨鲁米特1000mg/天+氢化可的松20mg/天，以及（b）氨鲁米特250mg/天。肿瘤芳香化酶值在0.05至2.07pmol雌激素生成量/mg蛋白质/小时之间，雌激素受体和孕激素受体值分别为小于1至249fmol类固醇结合量/mg蛋白质和小于1至132fmol类固醇结合量/mg蛋白质。芳香化酶值与雌激素受体或孕激素受体之间均无相关性，雌激素受体和孕激素受体与对氨鲁米特的反应之间也无相关性。然而，肿瘤芳香化酶值与治疗反应相关。反应者的平均芳香化酶水平（1.18±0.64pmol雌激素生成量/mg蛋白质/小时）显著高于无反应者（0.34±0.27）（t=5.20，自由度27；p<0.005）。14例芳香化酶值大于0.5pmol雌激素生成量/mg蛋白质/小时的患者中有10例有反应，而15例肿瘤芳香化酶值低于此值的患者中无1例有反应。两种剂量的氨鲁米特均可见反应。结论是，肿瘤芳香化作用将是预测对芳香化酶抑制剂反应的一项有用检测指标。
